FLOW CYTOMETRY SHARED RESOURCE Director: Philip R Streeter, PhD ABSTRACT / PROJECT SUMMARY The Knight Flow Cytometry Shared Resource provides Knight Cancer Institute members with state-of-the-art instrumentation, expertise, and infrastructure that fully support investigator needs for analytical flow cytometry and cell sorting. In the cancer setting, flow cytometry offers investigators a means of studying cells derived from diverse hematologic and solid cancers, non-cancerous cells from the microenvironments in which cancers reside, and cells from non-cancerous regions of the body. Flow cytometry facilitates the investigation of cells either at the population level or at the single cell level. In addition, the integrated use of cell isolation (by flow cytometry; within the Flow Cytometry Shared Resource) and downstream assessment of isolated cells (by proteomics or genomics; within the Proteomics Shared Resource and/or the Integrated Genomics Shared Resource) provides Knight investigators both the structure and technical expertise to facilitate highly complex interdisciplinary studies. The primary areas of focus for the Flow Cytometry Shared Resource staff are customer service/support, continuous improvement of standard flow cytometric technologies, and the introduction/establishment of new technologies or platforms to enable cutting-edge scientific investigation by Knight members. The services and technologies offered thru the Flow Cytometry Shared Resource are broadly supportive of Knight members, with nearly two-thirds of total Flow Cytometry Shared Resource usage by Knight members. Strategic decisions that impact the facility are made by the Knight senior leadership and the Flow Cytometry Shared Resource Advisory Committee. Support and services include: consultations, contributions to grant applications, education, training, data analyses, analytical flow cytometry, and cell sorting. Further, Knight investigators have the option of instrument self-use or operator-assisted use. The successful introduction/establishment of new technologies has allowed the Flow Cytometry Shared Resource to rapidly adapt to the changing needs of Knight members. By way of example, in 2012, a CyTOF instrument was purchased for the Flow Cytometry Shared Resource. The CyTOF, a mass cytometer, incorporates cytometry and mass spectroscopy, allowing investigators the potential to simultaneously analyze up to 34 parameters associated with individual cells. The resource also obtained a Luminex 200, an instrument enabling multiplex measurements of up to 100 analytes in solution. The technologies offered by the Flow Cytometry Shared Resource are having a positive transformative impact on research conducted by many investigators within the Knight. The establishment of new technologies has allowed the Flow Cytometry Shared Resource to have a central role in the research successes of many Knight members. During the next grant cycle, the Flow Cytometry Shared Resource will be expanded and new innovative platform technologies will be introduced to enable the Flow Cytometry Shared Resource staff to continue to meet the long-term needs of Knight members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA069533-20
Application #
9640136
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
20
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Medler, Terry R; Murugan, Dhaarini; Horton, Wesley et al. (2018) Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy. Cancer Cell 34:561-578.e6
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Davare, Monika A; Henderson, Jacob J; Agarwal, Anupriya et al. (2018) Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clin Cancer Res 24:6471-6482
Kurtz, Stephen E; Eide, Christopher A; Kaempf, Andy et al. (2018) Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia 32:2025-2028
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
Watson, Spencer S; Dane, Mark; Chin, Koei et al. (2018) Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Syst 6:329-342.e6
Li, Bingbing X; Chen, Jingjin; Chao, Bo et al. (2018) Anticancer Pyrroloquinazoline LBL1 Targets Nuclear Lamins. ACS Chem Biol 13:1380-1387

Showing the most recent 10 out of 277 publications